Pediatric Influenza Differential Diagnoses

1. U.S. Food and Drug Administration. Performance and Cautions in Using Rapid Influenza Virus Diagnostic Tests. Available at http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDeviceSafety/ucm109432.htm. Accessed: March 15, 2011.

2. [Guideline] Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011 Jan 21. 60 (1):1-24. [QxMD MEDLINE Link]. [Full Text].

3. Schünemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007 Jan. 7(1):21-31. [QxMD MEDLINE Link].

4. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15. 292(11):1333-40. [QxMD MEDLINE Link].

5. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8. 289(2):179-86. [QxMD MEDLINE Link].

6. Glezen WP. Orthomyxoviridae: Influenza viruses. Feigen RD. Textbook of Pediatric Infectious Diseases. 5th Ed. Philadelphia, PA: Saunders; 2004.

7. Horimoto T, Kawaoka Y. Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev. 2001 Jan. 14(1):129-49. [QxMD MEDLINE Link]. [Full Text].

8. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000 Nov 2. 343(18):1282-9. [QxMD MEDLINE Link].

9. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000 Mar 4. 355(9206):827-35. [QxMD MEDLINE Link].

10. Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev. 2007 Apr. 20(2):243-67. [QxMD MEDLINE Link]. [Full Text].

11. WHO. Responding to the avian influenza pandemic threat. 2005. WHO Recommendations. [Full Text].

12. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006 Oct. 12(10):1203-7. [QxMD MEDLINE Link].

13. Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011 Aug 12. 333(6044):843-50. [QxMD MEDLINE Link].

14. Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011 Aug 12. 333(6044):850-6. [QxMD MEDLINE Link].

15. CDC. Embargo of Birds from Specified Countries. Avian Influenza. Available at http://www.cdc.gov/flu/avian/outbreaks/embargo.htm.

16. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006 Jan. 12(1):9-14. [QxMD MEDLINE Link]. [Full Text].

17. Uiprasertkul M, Puthavathana P, Sangsiriwut K, Pooruk P, Srisook K, Peiris M, et al. Influenza A H5N1 replication sites in humans. Emerg Infect Dis. 2005 Jul. 11(7):1036-41. [QxMD MEDLINE Link].

18. Wong SS, Yuen KY. Avian influenza virus infections in humans. Chest. 2006 Jan. 129(1):156-68. [QxMD MEDLINE Link].

19. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004 Feb 21. 363(9409):617-9. [QxMD MEDLINE Link].

20. Gu J, Xie Z, Gao Z, Liu J, Korteweg C, Ye J, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007 Sep 29. 370(9593):1137-45. [QxMD MEDLINE Link].

21. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005 Sep 29. 353(13):1374-85. [QxMD MEDLINE Link].

22. FluView - Weekly U.S. Influenza Surveillance Report. CDC. Available at https://www.cdc.gov/flu/weekly/. 2023 Jul 08; Accessed: July 19, 2023.

23. Swine Influenza (Flu). Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/. Accessed: April 27, 2009.

24. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18. 360(25):2605-15. [QxMD MEDLINE Link].

25. Update: Novel Influenza A (H1N1) Virus Infection-- Worldwide, May 6, 2009. MMWR. May 2009. 58:453-8.

26. Libster R, Bugna J, Coviello S, Hijano DR, Dunaiewsky M, Reynoso N, et al. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Argentina. N Engl J Med. 2010 Jan 7. 362(1):45-55. [QxMD MEDLINE Link].

27. CDC. Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2010 Apr 16. 59(14):423-30. [QxMD MEDLINE Link].

28. Louie JK, Gavali S, Acosta M, Samuel MC, Winter K, Jean C, et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med. 2010 Nov. 164(11):1023-31. [QxMD MEDLINE Link].

29. US Department of Health and Human Services. Pandemic Flu. Pandemic Flu. Available at http://www.pandemicflu.gov/.

30. CDC. Isolation of avian influenza A(H5N1) viruses from humans--Hong Kong, May-December 1997. JAMA. 1998 Jan 28. 279(4):263-4. [QxMD MEDLINE Link].

31. Uyeki TM, Chong YH, Katz JM, Lim W, Ho YY, Wang SS, et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis. 2002 Feb. 8(2):154-9. [QxMD MEDLINE Link]. [Full Text].

32. Capua I, Alexander DJ. Avian influenza: recent developments. Avian Pathol. 2004 Aug. 33(4):393-404. [QxMD MEDLINE Link].

33. WHO. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. Epidemic and Pandemic Alert and Response (EPR). Available at http://www.who.int/csr/disease/avian_influenza/country/cases_table_2007_08_31/en/index.html.

34. WHO. Avian influenza – situation in Iraq. Epidemic and Pandemic Alert and Response (EPR). [Full Text].

35. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. World Health Organization. Available at http://www.who.int/csr/disease/avian_influenza/country/cases_table_2011_03_14/en/index.html. Accessed: March 14, 2011.

36. Mishra AC, Cherian SS, Chakrabarti AK, Pawar SD, Jadhav SM, Pal B, et al. A unique influenza A (H5N1) virus causing a focal poultry outbreak in 2007 in Manipur, India. Virol J. 2009 Feb 24. 6:26. [QxMD MEDLINE Link]. [Full Text].

37. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics. 2013 Nov. 132(5):796-804. [QxMD MEDLINE Link].

38. Waknine Y. Many Children Killed by Influenza Were Not High Risk. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/813520.. Accessed: November 12, 2013.

39. Centers for Disease Control and Prevention. Severe influenza among children and young adults with neurologic and neurodevelopmental conditions - ohio, 2011. MMWR Morb Mortal Wkly Rep. 2012 Jan 6. 60:1729-33. [QxMD MEDLINE Link].

40. Teo SS, Nguyen-Van-Tam JS, Booy R. Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps?. Arch Dis Child. 2005 May. 90(5):532-6. [QxMD MEDLINE Link]. [Full Text].

41. Hitt E. Influenza rapid tests show variable performance. Medscape Medical News. Nov 4, 2012. [Full Text].

42. Centers for Disease Control and Prevention. Evaluation of 11 commercially available rapid influenza diagnostic tests - United States, 2011-2012. MMWR Morb Mortal Wkly Rep. 2012 Nov 2. 61:873-6. [QxMD MEDLINE Link]. [Full Text].

43. CDC. New laboratory assay for diagnostic testing of avian influenza A/H5 (Asian Lineage). MMWR Morb Mortal Wkly Rep. 2006 Feb 10. 55(5):127. [QxMD MEDLINE Link].

44. CDC. Updated Interim Guidance for Laboratory Testing of Persons with Suspected Infection with Avian Influenza A (H5N1) Virus in the United States. Health Alert Network. Available at http://www2a.cdc.gov/han/ArchiveSys/ViewMsgV.asp?AlertNum=00246.

45. WHO. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. August 2007. Available at http://adc.bmj.com/content/90/5/532.full.

46. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005 Feb 17. 352(7):686-91. [QxMD MEDLINE Link].

47. Garg S, Fry AM, Patton M, Fiore AE, Finelli L. Antiviral treatment of influenza in children. Pediatr Infect Dis J. 2012 Feb. 31(2):e43-51. [QxMD MEDLINE Link].

48. Lam J, Nikhanj N, Ngab T, et al. Severe Cases of Pandemic H1N1 Pneumonia and Respiratory Failure Requiring Intensive Care. J Intensive Care Med. 2011 Sept-Oct. 26(5):318-25.

49. Moscona A. Oseltamivir resistance--disabling our influenza defenses. N Engl J Med. 2005 Dec 22. 353(25):2633-6. [QxMD MEDLINE Link].

50. Govorkova EA, Leneva IA, Goloubeva OG, Bush K, Webster RG. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother. 2001 Oct. 45(10):2723-32. [QxMD MEDLINE Link]. [Full Text].

51. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6. 379 (10):913-923. [QxMD MEDLINE Link].

52. CDC. CDC Recommends against the Use of Amantadine and Rimantadine for the Treatment or Prophylaxis of Influenza in the United States during the 2005–06 Influenza Season. Seasonal Flu. Available at http://www.cdc.gov/flu/han011406.htm.

53. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM Jr, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis. 2018 Dec 19. [QxMD MEDLINE Link]. [Full Text].

54. Baker J, Block SL, Matharu B, Burleigh Macutkiewicz L, Wildum S, Dimonaco S, et al. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2). Pediatr Infect Dis J. 2020 Aug. 39 (8):700-705. [QxMD MEDLINE Link]. [Full Text].

55. Ikematsu H, Hayden FG, Kawaguchi K, Kinoshita M, de Jong MD, Lee N, et al. Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. N Engl J Med. 2020 Jul 23. 383 (4):309-320. [QxMD MEDLINE Link]. [Full Text].

56. Centers for Disease Control and Prevention. Influenza Antiviral Drug Resistance. Available at http://www.cdc.gov/flu/about/qa/antiviralresistance.htm. Accessed: March 16, 2011.

57. Louie JK, Yang S, Samuel MC, Uyeki TM, Schechter R. Neuraminidase inhibitors for critically ill children with influenza. Pediatrics. 2013 Nov 25. [QxMD MEDLINE Link].

58. Brown T. Neuraminidase inhibitors improve survival in kids with flu. Medscape Medical News. November 25, 2013. [Full Text].

59. Rapivab (peramivir) [package insert]. Durham, NC: BioCryst Pharmaceuticals, Inc. September, 2017. Available at [Full Text].

60. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season. MMWR Morb Mortal Wkly Rep. 2017 Aug 25. 66(2):1-20. [Full Text].

61. [Guideline] Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2018. MMWR Morb Mortal Wkly Rep. 2018 Feb 9. 67 (5):156-157. [QxMD MEDLINE Link]. [Full Text].

62. Flannery B, Reynolds SB, Blanton L, et al. Influenza Vaccine Effectiveness Against Pediatric Deaths: 2010–2014. Pediatrics. April 2017.

63. Brown T. Pediatric Influenza Deaths Concentrated in Unvaccinated Kids. Medscape Medical News. Available at http://www.medscape.com/viewarticle/878093. April 03, 2017; Accessed: April 04, 2017.

64. Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, et al. Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. J Infect Dis. 2012 Sep. 206(6):828-37. [QxMD MEDLINE Link].

65. Troy Brown, RN. Nasal Flu Vaccine Back on CDC List of Recommended Vaccines. Medscape Medical News. 2018 Feb 22. Available at https://www.medscape.com/viewarticle/892970.

66. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med. 2017 Aug 10. 377 (6):534-543. [QxMD MEDLINE Link].

67. ACIP votes down use of LAIV for 2016-2017 flu season. Centers for Disease Control and Prevention (CDC) press release. 2016 Jun 22. Available at http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html.

68. [Guideline] Blanton L, Alabi N, Mustaquim D, Taylor C, Kniss K, Kramer N, et al. Update: Influenza Activity in the United States During the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2017 Jun 30. 66 (25):668-676. [QxMD MEDLINE Link]. [Full Text].

69. [Guideline] Grohskopf LA, Olsen SJ, et al. Influenza vaccination coverage among pregnant women--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2013 Sep 27. 62(38):787-92. [QxMD MEDLINE Link]. [Full Text].

70. Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for Prevention and Control of Influenza in Children, 2015-2016. Pediatrics. 2015 Oct. 136 (4):792-808. [QxMD MEDLINE Link].

71. Greenhawt M, Turner PJ, Kelso JM. Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017. Ann Allergy Asthma Immunol. 2018 Jan. 120(1):49-52. [Full Text].

72. Steinhoff MC, Omer SB, Roy E, Arifeen SE, Raqib R, Dodd C, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ. 2012 Feb 21. [QxMD MEDLINE Link].

73. Influenza vaccination coverage among pregnant women--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep. 2013 Sep 27. 62(38):787-92. [QxMD MEDLINE Link]. [Full Text].

74. Influenza Vaccine for the 2023-2024 Season. US Food and Drug Administration. Available at https://www.fda.gov/vaccines-blood-biologics/lot-release/influenza-vaccine-2023-2024-season. 2023 Jul 03; Accessed: July 27, 2023.

75. Cinti S. Pandemic influenza: are we ready?. Disaster Manag Response. 2005 Jul-Sep. 3(3):61-7. [QxMD MEDLINE Link].

76. CDC. Guidelines and Recommendations: Interim Guidance about Avian Influenza (H5N1) for U.S. Citizens Living Abroad. Traveler's Health. Available at http://wwwn.cdc.gov/travel/contentAvianFluAmericansAbroad.aspx.

77. FDA. FDA Approves First U.S. Vaccine for Humans Against the Avian Influenza Virus H5N1. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108892.htm. Accessed: March 16, 2011.

78. Lin JT, Li CG, Wang X, Su N, Liu Y, Qiu YZ, et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J Infect Dis. 2009 Jan 15. 199(2):184-7. [QxMD MEDLINE Link].

79. Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis. 2009 Mar 1. 199(5):711-6. [QxMD MEDLINE Link]. [Full Text].

80. Talbot TR, Bradley SE, Cosgrove SE, Ruef C, Siegel JD, Weber DJ. Influenza vaccination of healthcare workers and vaccine allocation for healthcare workers during vaccine shortages. Infect Control Hosp Epidemiol. 2005 Nov. 26(11):882-90. [QxMD MEDLINE Link].

81. Henderson, D. Influenza: Complications in 1 in 3 Previously Healthy Kids. Medscape Medical News. Available at http://www.medscape.com/viewarticle/829342. Accessed: August 4, 2014.

Itzhak Brook, MD, MSc Professor, Department of Pediatrics, Georgetown University School of Medicine

Itzhak Brook, MD, MSc is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians-American Society of Internal Medicine, American Medical Association, American Society for Microbiology, The Society of Federal Health Professionals (AMSUS), Infectious Diseases Society of America, International Immunocompromised Host Society, International Society for Infectious Diseases, Medical Society of the District of Columbia, New York Academy of Sciences, Pediatric Infectious Diseases Society, Society for Experimental Biology and Medicine, Society for Pediatric Research, Southern Medical Association, Society for Ear, Nose and Throat Advances in Children, American Federation for Clinical Research, Surgical Infection Society, Armed Forces Infectious Diseases Society

Disclosure: Nothing to disclose.

Hakan Leblebicioglu, MD Fellow, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Honorary Chair of ESCMID Study Group for Infections in Travelers and Migrants (ESGITM); Professor of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University School of Medicine, Turkey

Hakan Leblebicioglu, MD is a member of the following medical societies: American Society for Microbiology, European Society of Clinical Microbiology and Infectious Diseases

Disclosure: Nothing to disclose.

Anthony R Sambol, MA, SM, (NRM), SV(ASCP) Assistant Professor, Department of Pathology and Microbiology, University of Nebraska Medical Center; Assistant Professor, Division of Clinical Laboratory Science, School of Allied Health Professions, University of Nebraska Medical Center; Assistant Director of Nebraska Public Health Laboratory; Manager of Special Pathogens/Biosecurity Preparedness Lab for Biological, Chemical, and Radiological Preparedness

Disclosure: Nothing to disclose.

Meera Varman, MD Associate Professor, Department of Pediatrics, Section of Pediatric Infectious Diseases, Creighton University Medical Center

Meera Varman, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Microbiology, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Society for Healthcare Epidemiology of America

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Pfizer, Sanofi<br/>Received research grant from: Merck; MedImmune; Regenron; Pfizer;Novartis; Sanof; GSK<br/>Received honoraria from phamaceutical companies for speaking and teaching; Received grant/research funds from phamaceutical companies for clinical trials research.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Russell W Steele, MD Clinical Professor, Tulane University School of Medicine; Staff Physician, Ochsner Clinic Foundation

Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, Southern Medical Association

Disclosure: Nothing to disclose.

Leslie L Barton, MD Professor Emerita of Pediatrics, University of Arizona College of Medicine

Leslie L Barton, MD is a member of the following medical societies: American Academy of Pediatrics, Association of Pediatric Program Directors, Infectious Diseases Society of America, and Pediatric Infectious Diseases Society

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article